ArticleDer Urologe. Ausg. A2013
[Translational uroradio-oncology].
Article in Der Urologe. Ausg. A, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent developments and innovations in modern radiation oncology enable radiation oncologists to deliver a biologically, physically and technically stratified individualized treatment. In urological oncology, radiotherapy can be offered as a valid treatment alternative for a number of tumors, such as prostate cancer or urothelial cancer/bladder cancer.
methodsBy improving the precision of radiotherapy, significant improvement in tumor control can be achieved, coupled with a reduction of the risk of treatment-related side effects. Techniques such as high precision radiotherapy and combinations of radiation and modern imaging, such as image-guided radiotherapy (IGRT) and adaptive radiotherapy (ART), make daily individually tailored treatment possible.
conclusionsIn the future the biological characteristics of tumors and of normal tissue as well as molecular markers can be used for treatment stratification.
Indexed as
Identifiers
24026061What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.